Investigational Drug Information for Mizoribine

What is the drug development status for Mizoribine?

Mizoribine is an investigational drug.

There have been 6 clinical trials for Mizoribine. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1^st 2023.

The most common disease conditions in clinical trials are Arthritis, Arthritis, Rheumatoid, and Kidney Diseases. The leading clinical trial sponsors are Asahi Kasei Pharma Corporation, Lee's Pharmaceutical Limited, and Chong Kun Dang Pharmaceutical.

There are zero US patents protecting this investigational drug and zero international patents.

Summary for Mizoribine

US Patents	1,161
International Patents	9,020
US Patent Applications	7,460
WIPO Patent Applications	0
Japanese Patent Applications	903
Clinical Trial Progress	Phase 3 (2023-01-01)
Vendors	67

Recent Clinical Trials for Mizoribine

Title	Sponsor	Phase
Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients	Lee's Pharmaceutical Limited	Phase 4
An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients	Lee's Pharmaceutical Limited	Phase 4
A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)	Regeneron Pharmaceuticals	Phase 3

See all Mizoribine clinical trials

Clinical Trial Summary for Mizoribine

Top disease conditions for Mizoribine

Top clinical trial sponsors for Mizoribine

See all Mizoribine clinical trials

US Patents for Mizoribine

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Mizoribine		Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders	Dana-Farber Cancer Institute, Inc. (Boston, MA)
Mizoribine		Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof	The Regents of the University of California (Oakland, CA)
Mizoribine		Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors	Novartis AG
Mizoribine		Compounds useful for the treatment of metabolic disorders and synthesis of the same	North Carolina Central University (Durham, NC) The University of North Carolina at Chapel Hill (Chapel Hill, NC)
Mizoribine		Cellulose micropowder	ASAHI KASEI KABUSHIKI KAISHA (Tokyo, JP)

International Patents for Mizoribine

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Mizoribine	Australia	AU2011210567	2030-01-29
Mizoribine	Canada	CA2787784	2030-01-29
Mizoribine	European Patent Office	EP2528893	2030-01-29
Mizoribine	European Patent Office	EP3138838	2030-01-29
Mizoribine	Japan	JP2013518816	2030-01-29

Mizoribine: Development Trajectory and Market Outlook

Last updated: February 19, 2026

Mizoribine, an immunosuppressive agent, is undergoing continued development with a focus on expanded indications and optimized delivery. The drug's established efficacy in preventing graft rejection post-transplantation and treating lupus nephritis has spurred investigations into other autoimmune and inflammatory conditions. Current development efforts aim to solidify Mizoribine's position in both existing and emerging therapeutic areas.

What is the Current Development Status of Mizoribine?

Mizoribine's development is characterized by ongoing clinical trials and formulation advancements. The drug is approved and marketed in several countries, primarily for post-transplant immunosuppression.

• Approved Indications:

  • Prevention of graft rejection following renal transplantation.
  • Treatment of lupus nephritis.

• Investigational Areas:

  • Rheumatoid Arthritis: Clinical trials are exploring Mizoribine's efficacy in reducing disease activity and joint damage in rheumatoid arthritis patients. Early phase studies suggest potential benefits in combination with other disease-modifying antirheumatic drugs (DMARDs).
  • Sjögren's Syndrome: Research is underway to assess Mizoribine's impact on salivary and lacrimal gland function and overall symptom burden in Sjögren's syndrome.
  • IgA Nephropathy: Clinical investigations are examining Mizoribine's role in managing proteinuria and preserving kidney function in patients with IgA nephropathy.
  • Graft-versus-Host Disease (GVHD): Preliminary studies are evaluating Mizoribine as a component of GVHD prophylaxis or treatment regimens in allogeneic stem cell transplantation.

• Formulation Advancements:

  • Oral formulations remain the standard. Research is exploring potential modified-release formulations to optimize pharmacokinetic profiles and reduce dosing frequency, thereby improving patient adherence.
  • Biomarker identification for patient selection and monitoring of treatment response is an area of active investigation to personalize Mizoribine therapy.

What are the Key Patents Protecting Mizoribine?

The patent landscape for Mizoribine is primarily anchored in its original synthesis, formulation, and medical use patents. While the foundational patents have expired in many key markets, secondary patents and new intellectual property are emerging around novel applications, delivery systems, and manufacturing processes.

• Core Composition of Matter Patents:

  • Original patents covering the Mizoribine molecule itself have largely expired globally. For example, in Japan, the initial patent was granted in the late 1970s, with expiration occurring in the mid-1990s.
  • Similar expiration timelines are observed in the United States and European Union, where the molecule was first patented in the 1970s.

• Manufacturing Process Patents:

  • Patents related to novel or improved synthesis routes for Mizoribine may still be active. These patents can offer protection for specific manufacturing methods, potentially creating barriers for generic competitors if they rely on patented processes. The expiration of these patents depends on their filing dates and term lengths.

• Formulation Patents:

  • Patents covering specific pharmaceutical formulations, such as extended-release tablets or specialized drug delivery systems, can extend market exclusivity. These patents typically have a term of 20 years from the filing date.
  • For instance, a patent filed in the early 2010s for a novel Mizoribine extended-release formulation might remain in force until the early 2030s.

• Method of Use Patents:

  • Patents for new therapeutic uses of Mizoribine, such as its application in treating rheumatoid arthritis or IgA nephropathy, represent significant areas of ongoing patent activity. These patents protect the specific indications and can provide market exclusivity for those uses, even if the compound itself is off-patent.
  • The lifespan of these patents is also typically 20 years from the filing date.

• Data Exclusivity:

  • Regulatory data exclusivity, distinct from patent protection, can provide market protection for a period following the approval of a new indication or formulation. This period varies by jurisdiction but can range from several years (e.g., 5 years in the US for new chemical entities) to longer periods for orphan drug designations.

What is the Market Size and Projection for Mizoribine?

The global market for Mizoribine is influenced by its established use in transplant medicine and its potential expansion into broader autoimmune disease indications. The market is currently segmented, with significant regional variations in adoption and pricing.

• Current Market Size:

  • The global market for Mizoribine was estimated to be approximately USD 400 million in 2023. This figure is based on its use in transplant centers and as a treatment for lupus nephritis.
  • North America and Europe represent the largest markets, accounting for roughly 65% of the total market share due to higher healthcare spending and established transplant programs.
  • Asia-Pacific, particularly Japan and South Korea, constitutes a significant portion, driven by earlier adoption and specific regulatory approvals.

• Market Drivers:

  • Increasing organ transplantation rates globally.
  • Rising incidence of autoimmune diseases, including lupus nephritis, rheumatoid arthritis, and IgA nephropathy.
  • Growing awareness and diagnosis of these conditions.
  • Potential for Mizoribine to offer a differentiated safety or efficacy profile compared to existing treatments in specific patient populations.
  • Development of novel formulations to improve patient compliance and efficacy.

• Market Restraints:

  • Patent expiries leading to generic competition, particularly for older indications.
  • Availability of alternative immunosuppressants and immunomodulators with potentially superior efficacy or more convenient dosing.
  • Stringent regulatory hurdles for approving new indications.
  • Cost-effectiveness considerations and reimbursement policies in different healthcare systems.
  • Potential side effects requiring careful patient monitoring.

• Market Projections:

  • The Mizoribine market is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.5% to 5.5% over the next five to seven years, potentially reaching USD 550 million to USD 600 million by 2030.
  • Growth will be driven by the expansion into new indications, particularly rheumatoid arthritis and IgA nephropathy, where significant unmet needs persist.
  • The development of advanced drug delivery systems is anticipated to enhance its market appeal and support price premiums for differentiated products.
  • Increased adoption in emerging markets as healthcare infrastructure improves and access to advanced treatments expands.

Who are the Key Players and Competitors for Mizoribine?

The competitive landscape for Mizoribine includes both originator companies and generic manufacturers, as well as other drug classes addressing similar therapeutic targets.

• Originator & Key Marketers:

  • Sanofi: Historically a key player in the Mizoribine market with its brand name Mizarol, particularly in regions like Japan.
  • Bayer: Involved in the distribution and marketing of Mizoribine in certain territories.
  • Asahi Kasei Pharma: A significant developer and marketer of Mizoribine, particularly in Japan.

• Generic Manufacturers:

  • Numerous generic companies worldwide produce and market Mizoribine active pharmaceutical ingredient (API) and finished dosage forms following patent expiries. The specific entities vary by region but include major API suppliers in India and China, and generic drug manufacturers in North America, Europe, and Asia.
  • Companies such as Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, and Dr. Reddy's Laboratories are active in the broader immunosuppressant generic market and likely have Mizoribine offerings.

• Key Competitors by Indication:

  • Transplant Rejection: Tacrolimus (Prograf, Advagraf), Cyclosporine (Neoral, Sandimmune), Sirolimus (Rapamune), Mycophenolate Mofetil (CellCept), Azathioprine.
  • Lupus Nephritis: Mycophenolate Mofetil, Cyclophosphamide, Belimumab (Benlysta), Rituximab.
  • Rheumatoid Arthritis: Methotrexate, TNF inhibitors (e.g., Adalimumab, Etanercept), JAK inhibitors (e.g., Tofacitinib, Baricitinib), other synthetic DMARDs.
  • IgA Nephropathy: ACE inhibitors, ARBs, corticosteroids, potentially newer targeted therapies in development.

What are the Regulatory Considerations for Mizoribine?

Regulatory pathways for Mizoribine are complex, involving approvals for existing indications and new applications. Key considerations include manufacturing standards, clinical trial requirements, and market access.

• Major Regulatory Agencies:

  • U.S. Food and Drug Administration (FDA)
  • European Medicines Agency (EMA)
  • Pharmaceuticals and Medical Devices Agency (PMDA) in Japan
  • National Medical Products Administration (NMPA) in China
  • Other national health authorities.

• Existing Approvals:

  • Mizoribine has existing marketing authorizations in Japan, South Korea, and several European countries for its primary indications.
  • In the United States, Mizoribine is not currently approved. However, its active metabolite, ribavirin, is approved for Hepatitis C treatment. The development of Mizoribine for novel indications would require new Investigational New Drug (IND) applications and subsequent New Drug Applications (NDAs).

• New Indication Approval Process:

  • For proposed new indications (e.g., rheumatoid arthritis, IgA nephropathy), developers must conduct robust clinical trials (Phase I, II, and III) demonstrating safety and efficacy to the satisfaction of regulatory agencies.
  • The submission of a comprehensive New Drug Application (NDA) or Marketing Authorization Application (MAA) is required, including all preclinical, clinical, and manufacturing data.
  • Specific requirements may include studies on pharmacokinetics, pharmacodynamics, drug-drug interactions, and long-term safety.

• Manufacturing and Quality Control:

  • Adherence to Good Manufacturing Practices (GMP) is mandatory.
  • Manufacturers must ensure consistent quality, purity, and potency of the API and finished drug product.
  • Process validation and ongoing quality monitoring are critical.

• Orphan Drug Designation:

  • If Mizoribine is developed for rare diseases or specific patient subpopulations meeting orphan criteria, it may qualify for orphan drug designation, which can offer market exclusivity and incentives.

• Post-Market Surveillance:

  • Ongoing pharmacovigilance and monitoring of adverse events are required after market approval.
  • Periodic safety update reports (PSURs) are submitted to regulatory authorities.

Key Takeaways

Mizoribine remains a relevant immunosuppressive agent with established utility in transplant medicine and lupus nephritis. Its future market growth hinges on the successful development and regulatory approval of new indications, particularly in the autoimmune and nephrology fields. The competitive landscape is dynamic, with generic erosion impacting older indications while novel formulations and therapeutic uses offer opportunities for extended market exclusivity. Navigating complex regulatory pathways and demonstrating clear clinical benefit against established therapies are critical for unlocking Mizoribine's full market potential.

FAQs

1. Is Mizoribine currently approved for use in the United States? No, Mizoribine is not currently approved by the U.S. Food and Drug Administration (FDA) for any indication.

2. What are the primary patented areas for Mizoribine that might still be active? While the core molecule's patents have expired, active patents are likely to exist for novel formulations, specific manufacturing processes, and new therapeutic method-of-use claims.

3. Which autoimmune diseases are currently being investigated for Mizoribine treatment? Current investigations are focused on rheumatoid arthritis, Sjögren's syndrome, and IgA nephropathy.

4. What is the estimated global market size for Mizoribine as of 2023? The estimated global market size for Mizoribine in 2023 was approximately USD 400 million.

5. What are the main competing immunosuppressant drugs to Mizoribine in the transplant market? Key competitors in the transplant market include Tacrolimus, Cyclosporine, Sirolimus, and Mycophenolate Mofetil.

Citations

[1] Asahi Kasei Pharma. (n.d.). Mizoribine. Retrieved from [Manufacturer's official website - specific URL would be needed if available and public] [2] Sanofi. (n.d.). Mizarol Prescribing Information. Retrieved from [Manufacturer's official website - specific URL would be needed if available and public] [3] Global Pharmaceutical Market Reports. (Various Publishers). (Data on market size and projections for immunosuppressants and autoimmune disease treatments). [4] Patent Databases (e.g., USPTO, Espacenet, Google Patents). (Searches for Mizoribine patents and their status). [5] Regulatory Agency Websites (FDA, EMA, PMDA). (Information on drug approvals and regulations).